person · Reporting owner

MILANO VINCENT

Disclosed activity across 5 companies

Tapewire entity: 391
SEC CIK: 0001187159

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aceragen, Inc.ACGN · Entity 110652	Director	August 10, 2023	August 11, 2023
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 04, 2026	June 08, 2026
BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315	Director	August 31, 2026	September 02, 2026
Vanda Pharmaceuticals Inc.VNDA · Entity 5861	Director	June 13, 2018	June 15, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aceragen, Inc.

Report date August 10, 2023 · Filed August 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,987	Reported balance After 2023-08-10 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-08-10 · Sale · Disposed 3,283 · Balance 8,987 F1: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023. F3: Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023.

F3: Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units.

Aclaris Therapeutics, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,896	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 28,896 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03	Direct	42,350	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	10,987	Reported balance After 2026-06-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units vested on June 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

F3: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

F4: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

F5: The shares underlying these restricted stock units vested on June 5, 2026.

BIOCRYST PHARMACEUTICALS INC

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	109,642	Reported balance After 2026-08-31 transaction · row 1 1 source row Row 1 · 2026-08-31 · Grant · Acquired 1,159 · Balance 109,642 F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.

Vanda Pharmaceuticals Inc.

Report date June 13, 2018 · Filed June 15, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,000	Reported balance After 2018-06-13 transaction · row 1 1 source row Row 1 · 2018-06-13 · Grant · Acquired 5,000 · Balance 10,000 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2028-06-12	Direct	10,000	Reported balance After 2018-06-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-13 · Grant · Acquired 10,000 · Balance 10,000 F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Spark Therapeutics, Inc.

Report date December 17, 2019 · Filed December 17, 2019

Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-12-17 transaction · row 1 1 source row Row 1 · 2019-12-17 · Other · Disposed 3,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29	Direct	Reported balance After 2019-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30	Direct	Reported balance After 2019-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31	Direct	Reported balance After 2019-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11	Direct	Reported balance After 2019-12-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-12-17 · Disposition to issuer · Disposed 37,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 31, 2026 Filed Sep 2, 2026 20:10 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,159	$9.70	$11,242.30	Disclosure SEC source: 0000882796-26-000061 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,642 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500. Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:12 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	33,540	$0.00 Strike: $8.50	$0.00	Disclosure SEC source: 0000882796-26-000041 · form4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:12 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	15,294	$0.00	$0.00	Disclosure SEC source: 0000882796-26-000041 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,483 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001187159-26-000002 · form4-06082026_040607.xml · derivative · entry 4 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 5, 2026. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 5, 2026. Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	11,580	Not disclosed	Not disclosed	Disclosure SEC source: 0001187159-26-000002 · form4-06082026_040607.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	10,987	$0.00	$0.00	Disclosure SEC source: 0001187159-26-000002 · form4-06082026_040607.xml · derivative · entry 3 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Underlying: Common Stock · 10,987 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $4.71	$0.00	Disclosure SEC source: 0001187159-26-000002 · form4-06082026_040607.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:08 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	1,122	$8.91	$9,997.02	Disclosure SEC source: 0000882796-26-000027 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,189 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $20,000. Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:30 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	848	$8.75	$7,420.00	Disclosure SEC source: 0000882796-26-000009 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,067 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000. Read SEC document
November 28, 2025 Filed Dec 2, 2025 21:07 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	783	$7.18	$5,621.94	Disclosure SEC source: 0000882796-25-000019 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,219 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
August 29, 2025 Filed Sep 3, 2025 20:04 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	676	$8.31	$5,617.56	Disclosure SEC source: 0000882796-25-000003 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,436 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:21 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	27,181	$0.00 Strike: $10.40	$0.00	Disclosure SEC source: 0001171843-25-003917 · ownership.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:21 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0001171843-25-003917 · ownership.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,760 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016251 · form4-06092025_040610.xml · derivative · entry 4 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 6, 2025. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 6, 2025. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,793	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-016251 · form4-06092025_040610.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	11,580	$0.00	$0.00	Disclosure SEC source: 0001415889-25-016251 · form4-06092025_040610.xml · derivative · entry 3 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580 Underlying: Common Stock · 11,580 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:20 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	42,350	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0001415889-25-016251 · form4-06092025_040610.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date. F3 · balance_after: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy. Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:08 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	523	$10.75	$5,622.25	Disclosure SEC source: 0001127602-25-016424 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,260 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
February 28, 2025 Filed Mar 4, 2025 21:18 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	653	$8.61	$5,622.33	Disclosure SEC source: 0001127602-25-007884 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,737 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
November 29, 2024 Filed Dec 2, 2024 21:06 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	750	$7.50	$5,625.00	Disclosure SEC source: 0001127602-24-028290 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,084 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
August 30, 2024 Filed Sep 3, 2024 20:17 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	647	$8.69	$5,622.43	Disclosure SEC source: 0001127602-24-023304 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,334 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
June 12, 2024 Filed Jun 14, 2024 20:31 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	49,933	$0.00 Strike: $6.30	$0.00	Disclosure SEC source: 0001127602-24-018733 · form4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document
June 12, 2024 Filed Jun 14, 2024 20:31 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	6,820	$0.00	$0.00	Disclosure SEC source: 0001127602-24-018733 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,687 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,793	$0.00	$0.00	Disclosure SEC source: 0001415889-24-016196 · form4-06102024_040611.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,793 Underlying: Common Stock · 4,793 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:15 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001415889-24-016196 · form4-06102024_040611.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date. F2 · balance_after: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. Read SEC document
June 01, 2024 Filed Jun 4, 2024 20:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015365 · form4-06042024_040612.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2024. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2024. Read SEC document
June 01, 2024 Filed Jun 4, 2024 20:30 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,660	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-015365 · form4-06042024_040612.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
May 31, 2024 Filed Jun 3, 2024 20:29 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	870	$6.46	$5,620.20	Disclosure SEC source: 0001127602-24-017295 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,867 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
May 20, 2024 Filed May 22, 2024 11:21 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	PurchaseCommon Stock	15,000	$6.25	$93,750.00	Disclosure SEC source: 0001127602-24-016188 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,997 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $6.23 to $6.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document
February 29, 2024 Filed Mar 4, 2024 22:25 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	999	$5.63	$5,624.37	Disclosure SEC source: 0001127602-24-008156 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,997 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
November 30, 2023 Filed Dec 1, 2023 21:42 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	956	$5.88	$5,621.28	Disclosure SEC source: 0001127602-23-028609 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,998 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
August 31, 2023 Filed Sep 5, 2023 20:43 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	791	$7.11	$5,624.01	Disclosure SEC source: 0001127602-23-023695 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,042 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
August 10, 2023 Filed Aug 11, 2023 16:30 UTC	Aceragen, Inc. ACGN · Entity 110652	SaleCommon Stock	3,283	$0.53	$1,750.17	Disclosure SEC source: 0001415889-23-012142 · form4-08112023_040818.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,987 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023. F3 · balance_after: Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units. Read SEC document
June 13, 2023 Filed Jun 15, 2023 20:35 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	39,072	$0.00 Strike: $8.18	$0.00	Disclosure SEC source: 0001127602-23-018779 · form4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document
June 13, 2023 Filed Jun 15, 2023 20:35 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	16,745	$0.00	$0.00	Disclosure SEC source: 0001127602-23-018779 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,251 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document
June 02, 2023 Filed Jun 5, 2023 21:08 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034465 · doc4.xml · derivative · entry 4 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 2, 2023. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 2, 2023. Read SEC document
June 02, 2023 Filed Jun 5, 2023 21:08 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	4,507	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034465 · doc4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:08 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,660	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034465 · doc4.xml · derivative · entry 3 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:08 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $8.70	$0.00	Disclosure SEC source: 0001209191-23-034465 · doc4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:36 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	680	$8.27	$5,623.60	Disclosure SEC source: 0001127602-23-017562 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,506 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
February 28, 2023 Filed Mar 2, 2023 21:44 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	635	$8.85	$5,619.75	Disclosure SEC source: 0001127602-23-008400 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,826 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
November 30, 2022 Filed Dec 2, 2022 23:28 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	421	$13.36	$5,624.56	Disclosure SEC source: 0001127602-22-026828 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,191 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
August 31, 2022 Filed Sep 2, 2022 20:36 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	404	$13.90	$5,615.60	Disclosure SEC source: 0001127602-22-022018 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,770 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document
July 06, 2022 Filed Jul 7, 2022 17:29 UTC	Aceragen, Inc. IDRA · Entity 110652	GrantStock Option (Right to Buy) · Derivative	124,000	$0.00 Strike: $0.43	$0.00	Disclosure SEC source: 0001415889-22-007541 · form4-07072022_020720.xml · derivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2032-07-06 F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on July 6, 2026, with 25% vesting on July 6, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:51 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantAutomatic Stock Option Grant · Derivative	30,022	$0.00 Strike: $10.79	$0.00	Disclosure SEC source: 0001127602-22-017167 · form4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document
June 07, 2022 Filed Jun 9, 2022 20:51 UTC	BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315	GrantCommon Stock	12,866	$0.00	$0.00	Disclosure SEC source: 0001127602-22-017167 · form4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,366 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document
June 03, 2022 Filed Jun 6, 2022 21:24 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted Stock Units · Derivative	3,356	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034592 · doc4.xml · derivative · entry 4 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 3, 2022. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 3, 2022. Read SEC document
June 03, 2022 Filed Jun 6, 2022 21:24 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	3,356	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-034592 · doc4.xml · nonDerivative · entry 1 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
June 02, 2022 Filed Jun 6, 2022 21:24 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	4,507	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034592 · doc4.xml · derivative · entry 3 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507 Underlying: Common Stock · 4,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F4 · derivative.exercise_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date. Read SEC document
June 02, 2022 Filed Jun 6, 2022 21:24 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $14.48	$0.00	Disclosure SEC source: 0001209191-22-034592 · doc4.xml · derivative · entry 2 MILANO VINCENT · CIK 0001187159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2032-06-01 F2 · derivative.exercise_date: This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.